ORIC Pharmaceuticals, Inc. develops clinical-stage oncology therapies designed to counter mechanisms of therapeutic resistance in cancer. News about ORIC commonly covers rinzimetostat (ORIC-944), a selective allosteric PRC2/EED inhibitor studied in prostate cancer and metastatic castration-resistant prostate cancer, and enozertinib (ORIC-114), a brain-penetrant selective inhibitor targeting EGFR exon 20 insertion mutations and EGFR atypical mutations.
Recurring updates include clinical and preclinical data presentations, development-dose decisions, oncology conference presentations, quarterly financial results, cash runway disclosures, at-the-market equity financing, and Nasdaq Rule 5635(c)(4) inducement equity grants.
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) reported strong financial results and operational updates for Q1 2024. The company initiated three expansion cohorts for ORIC-114 and presented positive data for ORIC-944 in prostate cancer. Cash and investments stand at $331.5 million, ensuring funding until late 2026.
ORIC Pharmaceuticals, Inc. announced the granting of 14,500 non-qualified stock options and 2,300 restricted stock units to new non-executive employees under the 2022 Inducement Equity Incentive Plan. The grants were approved as inducements to employment and are subject to vesting conditions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.